Special Offer
| Chemical Structure | Cat. No. | Product Name | CAS No. |
|---|
 |
BCP01928 | MK-1775 Hot Discount | 955365-80-7 |
MK-1775 is a potent and selective Wee1 kinase inhibitor with an IC50 of 5.2 nM.
|
|||
 |
BCP20662 | LOXO-195 New Hot Discount | 2097002-61-2 |
LOXO-195 is a next-generation TRK kinase (TKI) inhibitor, with IC50s of 0.6±0.1 nM, <2.5 nM for TRKA and TRKC respectively.
|
|||
 |
BCP20339 | BMS-986205 New Hot Discount | 1923833-60-6 |
BMS-986205 is a selective indoleamine 2,3-dioxygenase 1 (IDO1) inhibitor.
|
|||
 |
BCP02532 | CAL-101 Discount | 870281-82-6 |
CAL-101 is a potent PI3K p110δ inhibitor with an IC50 of 65 nM.
|
|||
 |
BCP25378 | Physostigmine salicylate Discount | 57-64-7 |
Physostigmine salicylate is a reversible cholinesterase inhibitor, a parasympathomimetic alkaloid.
|
|||
 |
BCP17155 | GSK2330672 Hot Discount | 1345982-69-5 |
GSK2330672 is a highly potent, nonabsorbable ASBT(apical sodium-dependent bile acid transporter) inhibitor (hASBT IC50=42 ± 3 nM) which lowers glucose in an animal model of type 2 diabetes and shows excellent developability properties for evaluating the potential therapeutic utility of a nonabsorbable ASBT inhibitor for treatment of patients with type 2 diabetes.
|
|||
 |
BCP20294 | APR-246 Hot Discount | 5291-32-7 |
APR-246, also known as PRIMA-1MET, is a quinuclidinone derivative that targets the Wrap53 gene with potential antineoplastic activity. p53 activator APR-246 binds to and activates transcription of the Wrap53 gene, which results in an increase in WRAP53 p53 antisense transcript levels and, potentially, an increase in native p53 activity; in turn, increased p53 activity may lead to an induction of cell cycle arrest and apoptosis in tumor cells. This agent may work synergistically with other antineoplastic agents.
|
|||
 |
BCP05748 | Vistusertib Discount | 1009298-59-2 |
AZD2014 is a selective inhibitor of mTOR kinase.
|
|||
 |
BCP02640 | SelenocystaMine hydrochloride Discount | 3542-13-0 |
 |
BCP02523 | FG-4592 Discount Bulk | 808118-40-3 |
FG-4592 is an inhibitor of hypoxia inducible factor (HIF) prolyl hydroxylase currently in clinical development for the treatment of anemia.
|
|||
 |
BCP20094 | Nicotinamide Riboside Chloride Hot Discount Bulk | 23111-00-4 |
Nicotinamide riboside is a pyridine-nucleoside form of vitamin B3 that functions as a precursor to nicotinamide adenine dinucleotide or NAD+.
|
|||
 |
BCP14251 | Brivaracetam Hot Discount Bulk | 357336-20-0 |
Brivaracetam(UCB-34714) is a 4-substituted pyrrolidone butanamide as agent with significant antiepileptic activity; high affinity SV2A ligand and also shows an ability to inhibit Na+ channels.
|
|||
 |
BCP02884 | NSC 133723 Hot Discount | 19741-14-1 |
NSC 131463 is a dihydrofolate reductase potent inhibitor with an IC50 of 1 nM.
|
|||
 |
BCP18990 | AZD0156 Hot Discount | 1821428-35-6 |
AZD0156 is an oral, potent and selective ATM kinase inhibitor, inhibiting the kinase activity of ATM and ATM-mediated signaling, preventing DNA damage checkpoint activation, and disrupting DNA damage repair, inducing tumor cell apoptosis, and leading to cell death in ATM-overexpressing tumor cells.
|
|||
 |
BCP02515 | WZ4002 Discount | 1213269-23-8 |
WZ4002 is an EGFR T790M inhibitor(IC50<20nM).
|
|||
 |
BCP02829 | Bedaquiline Discount | 843663-66-1 |
Bedaquiline, also known as TMC207 and R207910, is a diarylquinoline anti-tuberculosis drug.
|
|||
 |
BCP04232 | Ulixertinib Discount | 869886-67-9 |
Ulixertinib(BVD-523&VRT752271) is a pyrrole inhibitors of ERK protein kinase.
|
|||
 |
BCP02173 | LY2157299 Discount | 700874-72-2 |
LY2157299 is a novel selective small molecule transforming growth factor beta receptor (TGF-βR) kinase inhibitor with IC50 of 86 nM and 2 nM for TβR1 and 2 nM, respectively.
|
|||
 |
BCP17698 | EAI045 Discount | 1942114-09-1 |
EAI045 is an allosteric inhibitor that targets selected drug-resistant EGFR mutants.
|
|||
 |
BCP02329 | Dolutegravir Discount | 1051375-16-6 |
Dolutegravir is an integrase inhibitor being developed for the treatment of human immunodeficiency virus (HIV)-1 infection by GlaxoSmithKline (GSK) on behalf of Shionogi-ViiV Healthcare LLC.
|
|||
